Drs. Demetri, Crawford, Cremieux and Cella are consultants to Ortho Biotech Products, L.P.
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
Version of Record online: 31 JUL 2002
Copyright © 2002 American Cancer Society
Volume 95, Issue 4, pages 888–895, 15 August 2002
How to Cite
Crawford, J., Cella, D., Cleeland, C. S., Cremieux, P.-Y., Demetri, G. D., Sarokhan, B. J., Slavin, M. B. and Glaspy, J. A. (2002), Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 95: 888–895. doi: 10.1002/cncr.10763
- Issue online: 31 JUL 2002
- Version of Record online: 31 JUL 2002
- Manuscript Accepted: 4 APR 2002
- Manuscript Revised: 1 APR 2002
- Manuscript Received: 2 JAN 2002
- Ortho Biotech Products, LP
- quality of life;
- epoetin alfa;
Hemoglobin increases have been associated with quality of life (QOL) improvements in anemic cancer patients treated with epoetin alfa, but intervention generally has been reserved for symptomatic anemia or hemoglobin < 10 g/dL. Relationships among hemoglobin, functional status, and patient reported QOL have not been well characterized.
Data from two open-label, community-based trials of epoetin alfa therapy that enrolled 4382 anemic cancer patients undergoing chemotherapy were used to evaluate the relationship between hemoglobin changes and QOL changes. The authors measured QOL using the Linear Analog Scale Assessment (LASA) and the more detailed, disease-specific Functional Assessment of Cancer Therapy-Anemia (FACT-An) instrument. Analyses were performed to determine the incremental change in QOL associated with hemoglobin increases (1 g/dL increments).
Cross-sectional analyses showed a nonlinear relationship and significant positive correlation between high hemoglobin levels and high LASA and FACT-An scores (r = 0.25 and 0.29, respectively, P < 0.01). Patients with hemoglobin increases of ≥ 2 g/dL reported statistically significant improvements in five FACT-An items selected a priori specifically to reflect functional capacity. An incremental analysis used regression methods to identify the longitudinal relationship between incremental changes in hemoglobin and QOL scores. This relationship was found to be nonlinear, with the maximum QOL gain occurring at a hemoglobin level of 12 g/dL (range, 11–13 g/dL). Patients with low baseline QOL scores and longer time periods between baseline and final QOL assessments experienced significantly (P < 0.05) greater increases in overall QOL. Progressive disease at baseline, change in disease status from baseline to end of study, and increase in self-reported pain or nausea all had significant (P < 0.05) negative effects on QOL scores.
A direct relationship exists between hemoglobin increases during epoetin alfa therapy and corresponding QOL improvements in cancer patients receiving chemotherapy across the clinically relevant hemoglobin range of 8–14 g/dL. These data suggest that the maximal incremental gain in QOL occurs when hemoglobin is in the range of 11–13 g/dL. Cancer 2002;95:888–95. © 2002 American Cancer Society.